Taletrectinib was approved for marketing in China in December 2024, becoming the second targeted therapy for ROS1 positive non-small cell lung cancer (NSCLC) after riptinib.
Drug localization and mechanism of action
Taletrectinib is an oral, potent, and selective next-generation ROS1 tyrosine kinase inhibitor (TKI) with central nervous system activity that can cross the blood-brain barrier. Its design targets ROS1 fusion gene mutations (accounting for approximately 1% -2% of NSCLC patients), by inhibiting the abnormally activated ROS1 signaling pathway and blocking tumor cell proliferation.
Indications and patient needs
Target population: ROS1 positive locally advanced or metastatic NSCLC patients, including untreated patients who have not received TKI treatment, as well as patients who have failed TKI treatment such as crizotinib.
Clinical significance: Due to its rarity and specificity, ROS1 mutations have limited efficacy in traditional chemotherapy and immunotherapy. Taletrectinib fills the gap in targeted therapy for such patients.
Clinical trial data support
TRUST-I study:
Initial treatment patients: Objective response rate (ORR) reached 91%, median duration of response (DOR) and median progression free survival (PFS) were not achieved (median follow-up of 23.5 months).
Patients resistant to crizotinib: ORR is 52%, median DOR is 10.6 months, and median PFS is 7.6 months.
TRUST-II study: further validated the efficacy and safety of the drug in a wider patient population, with data consistent with TRUST-I.
Intracranial therapeutic effect: It shows a higher intracranial ORR in patients with brain metastases, thanks to its blood-brain barrier penetration ability.
Resistance mutation coverage: Effective against common resistance mutations such as G2032R, breaking through the limitations of traditional TKIs.
In clinical trials of safety and tolerability, Taletrectinib has overall good safety. Common adverse reactions include nausea, diarrhea, fatigue, etc., which are mostly mild to moderate and can be relieved through supportive treatment. No serious or irreversible toxic reactions were found, and the impact on the patient's quality of life was relatively small.
